share_log

Bone Biologics Analyst Ratings

Benzinga Analyst Ratings ·  Oct 18, 2022 07:48
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/18/2022 326.14% EF Hutton → $2.25 Initiates Coverage On → Buy

Bone Biologics Questions & Answers

What is the target price for Bone Biologics (BBLG)?

The latest price target for Bone Biologics (NASDAQ: BBLG) was reported by EF Hutton on October 18, 2022. The analyst firm set a price target for $2.25 expecting BBLG to rise to within 12 months (a possible 326.14% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Bone Biologics (BBLG)?

The latest analyst rating for Bone Biologics (NASDAQ: BBLG) was provided by EF Hutton, and Bone Biologics initiated their buy rating.

When is the next analyst rating going to be posted or updated for Bone Biologics (BBLG)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bone Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bone Biologics was filed on October 18, 2022 so you should expect the next rating to be made available sometime around October 18, 2023.

Is the Analyst Rating Bone Biologics (BBLG) correct?

While ratings are subjective and will change, the latest Bone Biologics (BBLG) rating was a initiated with a price target of $0.00 to $2.25. The current price Bone Biologics (BBLG) is trading at is $0.53, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment